Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation transactions should be finished after this ..

<< Previous

Bullboard Posts

Next >>

Post by Mole101on Jun 06, 2021 5:10pm

286 Views

Post# 33337886

Amalgamation transactions should be finished after this ..

ilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$182,672 +41,296vol $4.42 each	54,193
2021-06-0613:26 2021-06-02	$ATE	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$77,636 +17,551 vol $4.42 each	26,662
2021-06-0613:22 2021-06-02	$ATE	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$306,889 +69,377vol $4.42 each	119,135
2021-06-0613:18 2021-06-02	$ATE	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$1,460,188 +330,098vol $4.42 each	442,729
2021-06-0613:16 2021-06-02	$ATE	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$6,620,347 +1,496,631vol $4.42 each	1,860,776
2021-06-0613:11 2021-06-02	$ATE	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$205,506 +46,458vol $4.42 each	126,100
2021-06-0613:09 2021-06-02	$ATE	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$2,637,909 +596,340vol $4.42 each	830,796
2021-06-0613:02 2021-06-03	$ATE	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-300,300 -75,000 vol $4.00 each	755,796
2021-06-0612:55 2021-06-03	$ATE	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-400,300 -100,000vol $4.00 each	385,027